|
Distribution of clinicopathological parameters: CA IX positive versus CA IX negative high-risk breast cancer patients |
||||
| CA IX positive |
CA IX negative |
χ2/P value |
||
|
|
||||
| All |
151 (16%) |
794 (84%) |
||
| Protocol |
Pre (DBCG82b) |
89 (59%) |
447 (56%) |
0.5 |
| Post (DBCG82c) |
62 (41%) |
347 (44%) |
||
| Tumour size (mm) |
<21 |
48 (32%) |
289 (36%) |
0.5 |
| 21 to 50 |
81 (54%) |
393 (49%) |
||
| >50 |
22 (15%) |
112 (14%) |
||
| Positive nodes |
None |
6 (3%) |
50 (6%) |
0.5 |
| 1 to 3 |
70 (46%) |
346 (44%) |
||
| >3 |
75 (50%) |
398 (50%) |
||
| Histopathology |
Ductal |
133 (88%) |
680 (86%) |
0.4 |
| Nonductal |
18 (12%) |
114 (14%) |
||
| Malignancy grade |
Grade 1 |
18 (12%) |
166 (21%) |
P < 0.0001 |
| Grade 2 |
56 (37%) |
357 (45%) |
||
| Grade 3 |
59 (39%) |
157 (20%) |
||
| Nonductal |
18 (12%) |
114 (14%) |
||
| ER |
Positive |
50 (33%) |
581 (73%) |
P < 0.0001 |
| Negative |
101 (67%) |
213 (27%) |
||
| PgR |
Positive |
47 (31%) |
506 (64%) |
P < 0.0001 |
| Negative |
104 (69%) |
288 (36%) |
||
| HER2 |
Negative |
101 (33%) |
636 (80%) |
P < 0.0001 |
| Positive |
50 (67%) |
636 (80%) |
||
|
Shown is the distribution of various clinicopathological parameters among carbonic anhydrase (CA) IX positive and CA IX negative high-risk breast cancer patients randomized to receive or not receive postmastectomy radiotherapy. ER, oestrogen receptor; HER, human epidermal growth factor; PgR, progesterone receptor. | ||||
Kyndi et al. Breast Cancer Research 2008 10:R24 doi:10.1186/bcr1981 |
||||